Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757891 | 1.00 | PIM1 (0.61) | PIM1AKR1B1PIM2NPC1RAB9A | |
| SCHEMBL27472329 | 1.00 | PIM1 (0.61) | PIM1AKR1B1PIM2NPC1RAB9A | |
| SCHEMBL5757894 | 1.00 | PIM1 (0.61) | PIM1AKR1B1PIM2NPC1RAB9A | |
| SCHEMBL27471393 | 0.89 | PIM1 (0.63) | PIM1AKR1B1PIM2NPC1RAB9A | |
| SCHEMBL8706547 | 0.88 | PTGS2 (0.55) | PIM1AKR1B1PIM2NPC1RAB9A | |
| SCHEMBL27463237 | 0.85 | MEN1 (0.59) | PIM1PIM2NPC1MEN1KMT2A | |
| SCHEMBL5758515 | 0.85 | MEN1 (0.59) | PIM1PIM2NPC1MEN1KMT2A | |
| SCHEMBL5757608 | 0.85 | MEN1 (0.59) | PIM1PIM2NPC1MEN1KMT2A | |
| SCHEMBL5758517 | 0.85 | MEN1 (0.59) | PIM1PIM2NPC1MEN1KMT2A | |
| SCHEMBL6614897 | 0.84 | MEN1 (0.58) | PIM1PIM2NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1142885-B1 | 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2006-11-15 | — | — | EP | claimed |
| EP-1179343-B1 | REMEDIES FOR DIABETES COMPRISING 2-(N-CYANOIMINO)THIAZOLIDINE-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2004-08-18 | — | — | EP | claimed |
| CN-1162152-C | Therapeutic agent for diabetes | ��ʽ���縻��Ħ���������� | 2004-08-18 | — | — | CN | claimed |
| US-6667328-B2 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO BROTHERS CO., LTD. (JP) | 2003-12-23 | — | — | US | claimed |
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO CO., LTD. (JP) | 2003-04-24 | — | — | US | claimed |
| CN-1358096-A | Remedies for diabetes | FUJIMOTO BROTHERS CO LTD (JP) | 2002-07-10 | — | — | CN | claimed |
| US-6380229-B1 | USEFUL FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDEMIA AND RELATED COMPLICATIONS | FUJIMOTO CO., LTD. (JP) | 2002-04-30 | — | — | US | claimed |
| EP-1179343-A1 | REMEDIES FOR DIABETES | Fujimoto Brothers Co., Ltd. (JP) | 2002-02-13 | — | — | EP | claimed |
| EP-1142885-A1 | NOVEL 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | Fujimoto Brothers Co., Ltd. (JP) | 2001-10-10 | — | — | EP | claimed |
| EP-1142885-B1 | 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2006-11-15 | — | — | EP | disclosed |
| EP-1179343-B1 | REMEDIES FOR DIABETES COMPRISING 2-(N-CYANOIMINO)THIAZOLIDINE-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2004-08-18 | — | — | EP | disclosed |
| CN-1162152-C | Therapeutic agent for diabetes | ��ʽ���縻��Ħ���������� | 2004-08-18 | — | — | CN | disclosed |
| US-6667328-B2 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO BROTHERS CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| CN-1358096-A | Remedies for diabetes | FUJIMOTO BROTHERS CO LTD (JP) | 2002-07-10 | — | — | CN | disclosed |
| US-6380229-B1 | USEFUL FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDEMIA AND RELATED COMPLICATIONS | FUJIMOTO CO., LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| EP-1179343-A1 | REMEDIES FOR DIABETES | Fujimoto Brothers Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-1142885-A1 | NOVEL 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | Fujimoto Brothers Co., Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | APOL1, NR1H2, CYP8B1 | PIM1 3125/4885AKR1B1 511/4885PIM2 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.